Skip to Main Content

Paper Details

Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.
Cancer Res
26
2016
Leukemia, TNK2, TNK2 kinase, Tyrosine, Tyrosine Kinase Nonreceptor 2 Mutations, XMD16-5, XMD8-87, acute myeloid leukemia, candidate, chronic myelomonocytic leukemia, dasatinib, gene targets, genomic lesions, leukemia, leukemia cells, mutant genes, patient, patients, primary, tumor, tumor types, tyrosine, tyrosine kinase nonreceptor 2
Author NameAffiliation
Julia E MaxsonKnight Cancer Institute, Oregon Health and Science University, Oregon. Clinical Research Division, Fred Hutchinson Cancer Research Center
Melissa L AbelKnight Cancer Institute, Oregon Health and Science University
Samuel B LutyKnight Cancer Institute, Oregon Health and Science University
Daniel BottomlyKnight Cancer Institute, Oregon Health and Science University, Oregon. Oregon Clinical and Translational Research Institute
Beth WilmotKnight Cancer Institute, Oregon Health and Science University, Oregon. Oregon Clinical and Translational Research Institute
Shannon K McWeeneyKnight Cancer Institute, Oregon Health and Science University, Oregon. Oregon Clinical and Translational Research Institute
Jerald P RadichClinical Research Division, Fred Hutchinson Cancer Research Center
Oliver HantschelSwiss Institute for Experimental Cancer Research (ISREC), Ecole polytechnique federale de Lausanne (EPFL)
Nathanael S GrayDana Farber Cancer Institute, Harvard Medical School
Nathanael S GrayDana Farber Cancer Institute, Harvard Medical School
Brian J DrukerKnight Cancer Institute, Oregon Health and Science University, Oregon. Howard Hughes Medical Institute
Jeffrey W TynerOregon Health and Science University
  • 1 - 12

Datasets

Release 1.2